Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

silence therapeutics - SLNCF

SLNCF

Close Chg Chg %
2.03 0.22 10.84%

Closed Market

2.25

+0.22 (10.84%)

Volume: 500.00

Last Updated:

Dec 22, 2025, 1:55 PM EDT

Trade Now

Company Overview: silence therapeutics - SLNCF

SLNCF Key Data

Open

$2.25

 Day Range

2.25 - 2.25

52 Week Range

0.50 - 2.63

 Market Cap

$318.83M

Shares Outstanding

141.70M

 Public Float

93.81M

Beta

0.90

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.79

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

101.00

  

SLNCF Performance

1 Week
 
 10.84%
 
1 Month
 
 40.62%
 
3 Months
 
 41.51%
 
1 Year
 
 -68.31%
 
5 Years
 
 N/A
 

SLNCF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Silence Therapeutics - SLNCF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
17.07M 21.56M 31.54M 43.26M
Sales Growth
+143.02% +26.26% +46.32% +37.14%
Cost of Goods Sold (COGS) incl D&A
10.84M 14.00M 12.83M 12.07M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
587.25K 593.72K 619.04K 593.00K
Depreciation
565.25K 588.79K 574.29K 336.00K
Amortization of Intangibles
22.00K 4.93K 44.75K 257.00K
COGS Growth
+98.55% +29.09% -8.36% -5.92%
Gross Income
6.23M 7.56M 18.72M 31.19M
Gross Income Growth
+298.07% +21.32% +147.51% +66.65%
Gross Profit Margin
+36.50% +35.08% +59.34% +72.10%
2021 2022 2023 2024 5-year trend
SG&A Expense
69.24M 67.42M 80.38M 80.77M
Research & Development
42.29M 43.85M 54.73M 54.15M
Other SG&A
26.95M 23.57M 25.65M 26.63M
SGA Growth
+60.23% -2.63% +19.22% +0.49%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(63.01M) (59.86M) (61.66M) (49.58M)
Non Operating Income/Expense
(46.76K) 1.57M (835.33K) 5.12M
Non-Operating Interest Income
13.75K 1.57M 1.80M 4.47M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 11.00K 57.89K 42.26K
Interest Expense Growth
-46.38% +426.19% -27.00% -100.00%
Gross Interest Expense
- 11.00K 57.89K 42.26K
Interest Capitalized
- - - -
-
Pretax Income
(63.07M) (58.35M) (62.54M) (44.46M)
Pretax Income Growth
-36.46% +7.48% -7.18% +28.90%
Pretax Margin
-369.36% -270.66% -198.27% -102.79%
Income Tax
(8.87M) (8.47M) (8.75M) 845.00K
Income Tax - Current - Domestic
(8.87M) (8.47M) (8.75M) 845.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(54.20M) (49.87M) (53.78M) (45.31M)
Minority Interest Expense
- - - -
-
Net Income
(54.20M) (49.87M) (53.78M) (45.31M)
Net Income Growth
-29.86% +7.98% -7.84% +15.76%
Net Margin Growth
-317.44% -231.35% -170.51% -104.74%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(54.20M) (49.87M) (53.78M) (45.31M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(54.20M) (49.87M) (53.78M) (45.31M)
EPS (Basic)
-0.6093 -0.5164 -0.4833 -0.3266
EPS (Basic) Growth
-19.38% +15.25% +6.41% +32.42%
Basic Shares Outstanding
88.95M 96.58M 111.28M 138.75M
EPS (Diluted)
-0.6093 -0.5164 -0.4833 -0.3266
EPS (Diluted) Growth
-19.38% +15.25% +6.41% +32.42%
Diluted Shares Outstanding
88.95M 96.58M 111.28M 138.75M
EBITDA
(62.42M) (59.26M) (61.04M) (48.99M)
EBITDA Growth
-52.20% +5.06% -3.00% +19.74%
EBITDA Margin
-365.58% -274.90% -193.52% -113.25%

Silence Therapeutics in the News